Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lu, C. Y.
Right arrow Articles by Vazquez, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lu, C. Y.
Right arrow Articles by Vazquez, M. A.

Journal of the American Society of Nephrology, Vol 4, 1239-1256, Copyright © 1993 by American Society of Nephrology

REVIEWS

Prevention and treatment of renal allograft rejection: new therapeutic approaches and new insights into established therapies

CY Lu, SC Sicher and MA Vazquez
Parkland Memorial Hospital, Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas 75235-8856.

Renal transplantation is the preferred treatment modality for patients with ESRD who are good surgical risks and able to comply with chronic immunosuppressive medications. Clinical transplantation has advanced significantly, with most transplant centers reporting 1-yr renal allograft survival rates of better than 80%. Nevertheless, rejection and a progressive loss of allografts over time continue to occur. The immunosuppressive agents currently used may lead to the development of life-threatening infections, malignancies, and advanced atherosclerosis as a consequence of some of their side effects. This review examines the mechanisms involved in allograft rejection as currently understood. The recent knowledge into the mechanism of action of cyclosporine, FK506, and rapamycin on T cell activation is presented. Information recently available on some of the established therapies such as steroids, antimetabolites and monoclonal antibodies as well as the newer agents is also discussed. The interaction between clinical transplantation and basic research in immunology continues to result in exciting advances in both fields.


This article has been cited by other articles:


Home page
 CirculationHome page
J. Lindenfeld, G. G. Miller, S. F. Shakar, R. Zolty, B. D. Lowes, E. E. Wolfel, L. Mestroni, R. L. Page II, and J. Kobashigawa
Drug Therapy in the Heart Transplant Recipient: Part II: Immunosuppressive Drugs
Circulation, December 21, 2004; 110(25): 3858 - 3865.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
X. M. Mueller
Drug immunosuppression therapy for adult heart transplantation. Part 1: immune response to allograft and mechanism of action of immunosuppressants
Ann. Thorac. Surg., January 1, 2004; 77(1): 354 - 362.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
A. Tsujikawa, Y. Ogura, N. Hiroshiba, K. Miyamoto, J. Kiryu, Y. Honda, and V. L. Dawson
Tacrolimus (FK506) Attenuates Leukocyte Accumulation After Transient Retinal Ischemia • Editorial Comment
Stroke, July 1, 1998; 29(7): 1431 - 1438.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673